-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Optimizing Oncology Care Through Biomarker Adoption
Barriers and Solutions
Sep 09, 2020
About the Report
Improvements in oncology care are being driven by the growing availability and use of biomarker testing. Such tests influence health outcomes by informing care teams whether a specific targeted therapy is likely to be effective for a specific patient. However, in routine care, levels of biomarker testing differ greatly across tumor types and by biomarker, with varying adherence to testing guidelines. This report discusses the major barriers that limit testing for solid tumor biomarkers in the United States and how they are evolving within a changing healthcare landscape. It further offers solutions to help reduce these testing barriers in oncology and ensure treatment benefits are fully realized.
Report Summary
An increased understanding of genetic and other molecular alterations in solid tumors — along with the development of targeted biomarker-based treatments for cancers with such alterations — have led to major improvements in patient care, overall survival, and quality of life outcomes. As such, biomarker testing has emerged as an important part of cancer care. However, there are several barriers to oncology biomarker testing for solid tumors including suboptimal tissue procurement and triaging; challenges with continuity of care across institutions; fragmented insurance coverage and inadequate reimbursement of testing; fragmented testing guidelines; and low awareness of actionable biomarkers by stakeholders. These result in operational inefficiencies in biomarker testing, limit awareness of available tests, and disincentivize broad and optimal use of testing. Collaboration across multiple stakeholders will be required to bring about a future with better patient outcomes through more robust diagnostic testing in cancer, and this report profiles potential solutions to help reduce testing barriers.
Key Findings
Optimal adoption of biomarker testing is necessary for cancer patients to reap the benefits of biomarker-based targeted therapies, yet testing rates vary greatly across biomarkers and tumor types.
Variability in Oncology Biomarker Testing Rates
- Within just a few months after the launch of the first BRAF-targeted treatment for melanoma, nearly 90% of patients who were potentially eligible for an associated treatment for metastatic melanoma were tested. However, many other biomarkers such as EGFR and ALK for NSCLC saw a much slower increase in testing after the first associated product came to market.
- While the use of biomarker testing is on the rise, slow and uneven adoption of biomarker testing can result in patients not receiving optimal treatments, potentially resulting in diminished patient outcomes and reduced survival.
- Poor testing rates represent a major hurdle in getting the right medicine to the right patient at the right time. Patients cannot fully realize the benefits of the precision medicine revolution in oncology without adequate biomarker testing to inform treatment decision-making.
As biomarker tests and biomarker-based medicines proliferate, the complexity of the patient journey has increased, and a number of barriers hinder optimal use of testing to guide therapy selection.
Barriers to the Use of Biomarker Tests Throughout the Patient Journey
- Suboptimal tissue procurement and triaging are significant clinical and technical barriers to tumor biomarker testing, and healthcare providers cite insufficient quantity of biopsy material as a key challenge to testing.
- Fragmented coverage of biomarker tests by payers can be a hurdle to optimal testing, particularly given the emergence of next-generation sequencing (NGS) technology and the simultaneous testing of multiple biomarkers via panels — both of which may be poorly covered.
- As the oncology treatment landscape becomes more crowded with predictive biomarker-based therapies within overlapping patient populations, fragmented testing guidelines compound challenges in treatment decision-making.
With an ever-growing focus on personalized medicine, changes that address testing barriers and spur a robust uptake of biomarker testing in oncology care can enable a future with better patient outcomes.
Recommendations to Overcome Barriers to Biomarker Testing
- In order to optimize biomarker testing in oncology, systems need to be in place to guide the efficient extraction, triaging, and handling of tumor tissue to support testing.
- Payer reimbursement policies may need to evolve to determine when coverage of a multigene panel test should occur in place of single, targeted genetic test to ensure patients don’t shoulder the burden of high out-of-pocket costs.
- There is a need to better integrate both treatment and biomarker testing recommendations into the same guidelines to understand whom to test, when to test, which biomarkers should be tested for, and how best to test for them. Updating guidelines will require input and collaboration across a range of experts, including both oncologists and pathologists, among others.
